Enoxaparin and antifactor Xa levels in pediatric acute burn patients

Journal of Burn Care and Research

Volumn 34, Issue 6, 2013, Pages 628-632

  Brown, Amalia ^a,b   Faraklas, Iris ^a,b   Ghanem, Maureen ^a,b   Cochran, Amalia ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN;

ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BURN; BURN PATIENT; CHILD; CHILDHOOD INJURY; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HEMATOMA; HOSPITALIZATION; HUMAN; INJURY SEVERITY; LENGTH OF STAY; MALE; PEDIATRICS; SCHOOL CHILD; SEX DIFFERENCE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BURN UNITS; BURNS; CHILD; CHILD, PRESCHOOL; ENOXAPARIN; FEMALE; HUMANS; INFANT; LENGTH OF STAY; MALE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84892815594     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3182a2a9f8     Document Type: Article

References (10)

1. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009;124:1001-8.
2. Hanson SJ, Punzalan RC, Greenup RA, Liu H, Sato TT, Havens PL. Incidence and risk factors for venous thromboembolism in critically ill children after trauma. J Trauma 2010;68:52-6.
3. Lin H, Faraklas I, Cochran A, Saffle J. Enoxaparin and antifactor Xa levels in acute burn patients. J Burn Care Res 2011;32:1-5.
4. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940-4.
5. Branchford BR, Mourani P, Bajaj L, Manco-Johnson M, Wang M, Goldenberg NA. Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. Haematologica 2012;97:509-15.
6. Hanson SJ, Punzalan RC, Arca MJ, et al. Effectiveness of clinical guidelines for deep vein thrombosis prophylaxis in reducing the incidence of venous thromboembolism in critically ill children after trauma. J Trauma Acute Care Surg 2012;72:1292-7.
7. Merkel N, Gunther G, Schobess R. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol 2006;115:230-6.
8. Fung LS, Klockau C. Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients. J Pediatr Pharmacol Ther 2010;15:119-25.
9. Sanchez de Toledo J, Gunawardena S, Munoz R, et al. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit? Cardiol Young 2010;20(2):138-43.
10. Jaehde U, Sörgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995;29:15-28.